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People with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) often report a high frequency of viral
infections and flu-like symptoms during their disease course. Given that this reporting agrees with different
immunological abnormalities and altered gene expression profiles observed in the disease, we aimed at answering
whether the expression of the human angiotensin-converting enzyme 2 (ACE2), the major cell entry receptor for
SARS-CoV-2, is also altered in these patients. In particular, a low expression of ACE2 could be indicative of a high
risk of developing COVID-19. We then performed a meta-analysis of public data on CpG DNA methylation and
gene expression of this enzyme and its homologous ACE protein in peripheral blood mononuclear cells and related
subsets. We found that patients with ME/CFS have decreased methylation levels of four CpG probes in the ACE
locus (cg09920557, cg19802564, cg21094739, and cg10468385) and of another probe in the promoter region of
the ACE2 gene (cg08559914). We also found a decreased expression of ACE2 but not of ACE in patients when
compared to healthy controls. Accordingly, in newly collected data, there was evidence for a significant higher
proportion of samples with an ACE2 expression below the limit of detection in patients than healthy controls.
Altogether, patients with ME/CFS can be at a higher COVID-19 risk and, if so, they should be considered a priority
group for vaccination by public health authorities. To further support this conclusion, similar research is rec-
ommended for other human cell entry receptors and cell types, namely, those cells targeted by the virus.. Sotzny), nunosep@gmail.com (N. Sepúlveda).
3 June 2021; Accepted 23 July 2021
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Malato et al. Heliyon 7 (2021) e076651. Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is
a multifactorial and complex disease characterized by two key symp-
toms: (1) persistent but unexplained fatigue that is not alleviated by
rest; and (2) post-exertional malaise upon minimal physical or even
mental effort [1, 2]. Although its cause remains unknown, a growing
body of evidence strongly associates ME/CFS with several microbial
and viral infections, as potential triggering factors [3, 4]. In addition, it
is currently hypothesized that reactivations of dormant viral infections
also play a role [5, 6] due to several immunological abnormalities [7, 8,
9]. On the molecular basis of the disease, peripheral blood mononuclear
cells (PBMCs) have altered gene expression profiles [10], including a
decreased abundance of the human angiotensin-converting enzyme 2
(ACE2) [11], the main receptor of the severe acute respiratory syn-
drome coronavirus-2 (SARS-CoV-2) for cell invasion [12, 13, 14].
Altogether, this evidence raises the question about the COVID-19 risk in
patients with ME/CFS.
As basic information, ACE2 is encoded by the X-linked ACE2 gene
whose expression is predominant in the lungs, heart, skin, and kidneys
[15, 16, 17, 18]. Its expression can also be detected in monocytes [19]
and activated macrophages [20]. However, the percentage of
ACE2-expressing cells is below 5% in the main immune-cell populations
[20]. Accordingly, current RNA-Seq studies suggest a residual ACE2
expression in PBMCs from healthy controls [18]. ACE2 has an
amino-acid sequence identity of 41% with its homologous
angiotensin-converting enzyme (ACE) [21]. This sequence similarity
increases to 61% at the nucleotide level [21]. The enzymes ACE and
ACE2 are members of the renin-angiotensin-aldosterone system (RAAS),
which regulates blood pressure and vascular resistance [22]. In partic-
ular, ACE and ACE2 have vasoconstriction and vasodilation effects,
respectively. Given this counteracting effect, high ACE:ACE2 ratios are
possible indicators of severe COVID-19 outcomes, linked to increased
reactive oxygen species (ROS) production, vasoconstriction, and
inflammation [23].
To answer our research question, we performed a meta-analysis of
public DNA methylation and gene expression data of ACE2 and ACE in
PBMCs. Similar study was conducted on the DNA methylation pattern of
ACE2 in the same cell type from patients with systemic lupus erythe-
matosus [24], an autoimmune disease whose symptoms overlap with the
ones from ME/CFS [25]. To complement our findings, we also compared
the mRNA levels of these two genes in PBMCs from a new cohort of fe-




n Sample characteristics Case definit
[27] CD4þ T cells 25 Female/male adults
Mean age: 50 years old
Mean BMI: not reported
1994 CDC/F
[28] PBMC 12 Female adults
Mean age: 41 years old
Mean BMI: 23 kg/m2
1994 CDC/F
2003 CCC
[29] PBMC 49 Female adults




[30] PBMC 13 Female adults




[32] T lymphocytes 61 Female/male adults
Mean age: 32 years old
Mean BMI: 27 kg/m2
1994 CDC/F
2003 CCC
[33] PBMC 10 Female/male adults
Mean age: Not reported
Mean BMI: not reported
2003 CCC
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2. Materials and methods
2.1. Eligible diagnostic criteria of ME/CFS
In our meta-analysis, we selected public data from studies using either
the 1994 Centre for Diseases Control criteria (1994 CDC/Fukuda) [1] or
the 2003 Canadian Consensus Criteria (2003 CCC) [2] for the disease
diagnosis. These criteria are defined by the presence of several key
symptoms while excluding known medical conditions (e.g., multiple
sclerosis or lupus) that can also explain fatigue. The choice of using these
two criteria for study selection complies with the research standards set
by the European Network on ME/CFS [26].2.2. Analysis of published DNA methylation association studies
Our meta-analysis was based on six genome-wide DNA methylation
association studies (Table 1), four of which [27, 28, 29, 30] were pre-
viously reviewed [31], and other two published after this review [32,
33]. Briefly, these studies aimed at identifying differentially methylated
CpG dinucleotide sites between patients and healthy controls. Illumina
methylation arrays were used to measure the respective DNA methyl-
ation levels with the exception of a single study (Table 1). In this study,
the measurements were made by the reduced representation bisulfite
sequencing [33].
With respect to the exclusion criteria, one study excluded individuals
who were taking beta-blockers or ACE inhibitors [30]. Three studies
excluded participants who were treated with immunomodulatory effects
or affecting the underlying DNA methylation levels at the time of data
collection [28, 29, 32].
In four of the published DNA methylation studies, patients and
healthy controls were matched for age, gender, and body mass index
(Table 1) [28, 29, 30]. In two other studies, the matching was only based
on age and gender [27, 33]. Ethnicity was also used for further matching
[30, 32] or the same matching could be assumed in studies that only
recruited white females [28, 29]. The DNA methylation levels were
quantified in CD4þ T cells [27], PBMCs [28, 29, 30, 33], and T lym-
phocytes [32].
We conducted a joint analysis of the four array-based studies which
made the data available [28, 29, 30, 32]. We first retrieved the data from
all the CpG probes located in the coding regions and the transcription
starting sites (TSS) of ACE and ACE2, respectively. We then restricted our
data analysis to the 27 probes shared between the InfiniumHealthy
controls, n




ukuda 18 Infinium HumanMethylation450K
Array (Illumina)
NA
ukuda & 12 Infinium HumanMethylation450K
Array (Illumina)
GSE59489
ukuda 25 Infinium HumanMethylation450
Array (Illumina)
GSE93266
ukuda & 12 Methylation EPIC Array (Illumina) GSE111183
ukuda & 48 Infinium HumanMethylation450K
Array (Illumina)
GSE156792




















































































































































Figure 1. DNA methylation analysis of 19 and 8 CpG probes located in the ACE and ACE2 genes, respectively. (A) Minor allele frequency in European and North
American populations of SNPs located in the probes under analysis (see the respective data in Supplementary Table 2). (B) Boxplot of all possible Pearson's correlation
coefficients (y axis) between the M-values of the probes under analysis. Horizontal dashed line represents the situation of lack of correlation. (C) Adjusted p-values for
the overall association between each probe and ME/CFS. Adjusted p-values were calculated according to the Benjamini-Hochberg procedure with a false discovery rate
of 5% (dashed line). Grey areas in the plots represent the TSS of the genes. (D) and (E) The same analyses as shown in C but for women and men separately.
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J. Malato et al. Heliyon 7 (2021) e07665HumanMethylation450K and the Infinium HumanMethylationEPIC ar-
rays (Supplementary Table 1).
Before conducting the statistical analysis itself, we checked whether
(1) the selected probes showed a high probability of detection, (2) they
were not cross-reactive with other genomic regions, and (3) they were
not affected by single nucleotide polymorphisms (SNPs) with high minor
allele frequencies [34]. In the latter criterion, the SNPs included in the
selected probes had a minor allele frequency less than 5% in Europeans
and North Americans (Figure 1A; Supplementary Table 2) referring to the
sampled populations of the studies. All probes passed the remaining basic
quality control checks.
We analyzed the M-values of a given probe instead of the respective
β-values to ensure a good approximation of the Normal distribution to
the data [35]. Briefly, the β-values were calculated as the proportion of
the methylation signal relative to the total signal for a given probe. The
M-values were finally obtained by applying a logit transformation to the
β-values.
To analyze the M-values of each probe, we initially estimated a linear
regression model where the respective covariates were the study indi-
cator and the disease status of the participants. In this model, we included
the main effects of the covariates and the interaction. The model pa-
rameters were then estimated by the maximum likelihood method. Note
that the main effect of the disease status is usually seen as the pooled
effect of this covariate across all studies, as done in meta-analysis.
We then simplified the model using a backward stepwise procedure
based on Akaike's information criteria. Since the effect of the study in-
dicator was significant for the data of each probe, we tested the associ-
ation between ME/CFS and a given probe using a likelihood ratio test. In
this test, we compared the model including the study indicator only with
the best model including that covariate and the one associated with
disease status (i.e., either the model only including the main effects or the
model including both main effects and the interaction term).
To control for multiple testing, we adjusted the raw p-values using the
Benjamini-Hochberg procedure [36]. This adjustment ensured a false




n Sample characteristics Case definition
[38] PBMCs 5 Female adults
Mean age: 42 years old
Mean BMI: not reported
1994 CDC/Fukuda
[39] PBMCs 25 Female/male adults
Mean age: 41 years old
Mean BMI: not reported
1994 CDC/Fukuda
[40] Whole blood 25 Female/male adults
Mean age: 43 years old
Mean BMI: not reported
1994 CDC/Fukuda
[41] Whole blood 11 Female/male adults
Mean age: 34 years old
Mean BMI: 20.3 kg/m2
1994 CDC/Fukuda
[42] Muscle biopsies 4 Female/male adults
Mean age: 45/37 years old
Mean BMI: not reported
1994 CDC/Fukuda
[43] PBMCs 8 Male adults
Median age: 36 years old
Mean BMI: not reported
1994 CDC/Fukuda
[11] PBMCs 37 Female/male adults
Mean age: 51 years old
Mean BMI:29.4 kg/m2
1994 CDC/Fukuda
[44] PBMCs 33 Female/male adults
Mean age: not reported
Mean BMI: not reported
1994 CDC/Fukuda
a Data shared as a supplementary file in the online version of the study.
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Pearson's correlation coefficient was used to check the validity of this
assumption (Figure 1B).
We also repeated the same association analysis for women and men
separately. Note that three studies only recruited women [28, 29, 30]
while the remaining study recruited both men and women [32]. In the
latter study, there was no information available about the gender of each
participant. In this case, we estimated this missing information using the
function getSex of the R package minfi applied to the genome-wide DNA
methylation data [37]. The resulting frequencies of men and women
matched with those reported in the original study.
In the women-specific analysis, we performed the same association
analysis as described above. In the men-specific analysis, we compared a
linear regression model with the disease status as the single covariate
against another model without that covariate, when analyzing data from
each probe. The comparison was done by the likelihood ratio test whose
p-values were then adjusted for multiple testing in the same way as
described above.
Finally, for the study which did not share the respective data [27], we
checked whether the reported differentially methylated CpG probes were
located in either ACE or ACE2 (see Table 1 from this study). We did the
same for the study based on the reduced representation bisulfite
sequencing technology [33] (see Additional File 1 from this study).
2.3. Analysis of gene expression studies
Our meta-analysis of gene expression studies was focused on eight
reports using microarray technology (Table 2) [11,38–44]. These studies
complied with the Minimum Information about a Microarray Experiment
(MIAME) standard [45] and, therefore, they were considered to have
sufficient quality for their inclusion in the meta-analysis. In particular,
these studies normalized the data which ensured comparability between
different samples and between differentmeasurements of the same genes.
Gene expression of these studies was performed in PBMCs (5 studies),
whole blood (2 studies) and muscle biopsies (one study). One study
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50 GeneChip Human Genome
U133 Plus 2.0 (Affymetrix)
Yes/Yes No (NA)
11 Custom microarray (NA) Yes/No Yes (NA)a
5 Operon V2.0 (CRIBI
University of Padova)
Yes/Yes No (NA)
7 GeneChip Human Genome
U133 (Affymetrix)
Yes/Yes Yes (GSE14577)
25 MWG 20K human Array
(Biotech MWG)
Yes/Yes No (NA)
21 GeneChip Human Gene ST
(Affymetrix)
Yes/No No (NA)
J. Malato et al. Heliyon 7 (2021) e07665Another study reviewed the medications taken by the participants [11].
However, it was unclear which medications were considered as a part of
the exclusion criteria. A third study reported that healthy controls were
free from any medication at the time of sampling [41].
Three additional studies using microarray technology [46, 47, 48]
were excluded from our meta-analysis due to unclear or ineligible case
definitions of ME/CFS. We also excluded four RNA-seq studies [49, 50,
51, 52], because of insufficient reporting on the basic quality control
checks. In particular, these studies did not report the percentage of reads
that could bemapped onto the reference transcriptome, the percentage of
the transcriptome covered, the average number of mapped reads per
transcript, the relationship between the GC content and the mapped read
distribution, as recommended elsewhere [53]. More importantly, given


































































Figure 2. Boxplots per study, group and gender of the M-values referring to prob
Significant probe located in ACE2.
5
not explain how their mapping algorithms dealt with reads that could be
ambiguously mapped onto different locations in the transcriptome.
The selected studies were conducted in small cohorts of patients with
ME/CFS (mean sample size ¼ 18.5; range ¼ 4–37) and healthy controls
(mean sample size ¼ 18.6; range ¼ 5–50 individuals) (Table 2). In these
studies, the patients and healthy controls were matched for age and
gender. Different commercial and custom microarray technologies were
used for the respective gene expression quantification. There was only
one study in which the microarray did not include any probe in the genes
of interest [38]. Another study used a custom array based on 9,522 genes
from the RefSeq database, as available in August 2002 [39]. However,
this study did not provide the list of genes included in the respective
microarray. In terms of data sharing, one studymade the data available in















































es identified in Figures 1C and 1D. (A) Significant probes located in ACE. (B)
J. Malato et al. Heliyon 7 (2021) e07665[41]. The latter study used a custom microarray that measured the
expression of stress-related genes including ACE but excluding ACE2.
Before conducting a meta-analysis of the available data, we first re-
analyzed two studies where the normalized data were available [41,
43]. In the first study [41], we calculated the mean of the log2(fold--
change) for ACE and the respective standard error. Note that the
microarray used in this study did not include any probe in ACE2. In the
second study [43], we initially calculated the mean and the respective
standard error of the log2(fold-change) for each probe located in ACE and
ACE2. We then pooled each pair of means for the same gene using the
inverse-variance weighting method [54]. A third study reported the
mean of the log2(fold-change) for ACE2 and the respective p-value using
a two-tailed Student's test [11]. In this case, we determine the quantile of
the t-distribution associated with half of the reported p-value, equated it
to the test statistic, and solved the resulting equation as a function of the
standard error. No information was available from this study concerning
the expression levels of ACE.
Finally, we pooled the different estimates for the same gene from
different studies using the inverse-variance weighting method [54].2.4. Analysis of new RNA data on the ACE/ACE2 gene expression in ME/
CFS
2.4.1. Study participants
Thirty-seven women with ME/CFS were recruited in 2020 from the
outpatient clinic for immunodeficiencies at the Institute for Medical
Immunology at the Charite-Universit€atsmedizin Berlin, Germany. These
patients were diagnosed according to the 2003 CCC while excluding
other medical or neurological diseases which could explain fatigue [2].
Thirty-four women with self-reported healthy status were recruited from
staff.
2.4.2. Experimental procedure for RNA isolation and expression
Consistently with previous studies of ME/CFS, the gene expression
quantification was performed in PBMCs. These cells were isolated from
heparinized whole blood by density gradient centrifugation using Biocoll
Separating Solution (Merck Millipore). Total RNA was isolated and
extracted from 2106 PBMCs according to the manufacturer's in-
structions (NucleoSpin RNA Kit, Macherey-Nagel, cat. nr. 740955.50).
Afterwards cDNA was prepared by reverse transcription (High-Capacity
cDNA Reverse Transcription Kit, Applied Biosystems, cat. nr. 4368814)
and real-time PCR was performed using TaqMan® Universal PCR Master
Mix (cat. nr. 4305719) and TaqMan® Gene Expression Assays (cat. nr.
4331182) for ACE (Hs00174179_m1), ACE2 (Hs01085333_m1) and the
housekeeping gene HPRT1 (Hs02800695_m1) (Applied Biosystems). The
amplification of ACE and HPRT1was based on 20 ng template cDNA. For
the amplification of ACE2, this quantity was increased to 100 ng. All
measurements were performed with the ABI7200 and software Step One
Plus as absolute quantification according to manufacturer's instruction.
Relative gene expression was analysed using the ΔCT method.
2.4.3. Statistical analysis
We first tested whether patients and healthy controls were matched
for age using the Kolgomorov-Smirnov test for two independent samples.
For statistical convenience, gene expression values were independently
transformed for ACE and ACE2 using a Box-Cox transformation [55]. The
parameter estimates of this transformation were 0.303 and 0.225 for ACE
and ACE2, respectively. The transformed values for each gene were then
analyzed as the outcome variable of a linear regression model specifying
age and disease status of the participants as the respective covariates. The
linear regression model was estimated using the maximum likelihood
method. After estimating themodels, we tested the normal distribution in
the resulting residuals using the Shapiro-Wilk test. We also visually
inspected the assumption of constant variance of the same residuals as a
function of the covariates.6
Note that we were unable to quantify the ACE2 expression in 11
patients due to cDNA material below the limit of detection. These
problematic samples could be due to a lower expression of ACE2 in ME/
CFS patients than in healthy controls. To test this hypothesis, we
compared the respective proportion of samples below the limit of
detection using the Pearson's χ2 test for two-way frequency tables.
The significance level of the statistical analysis was set at 5%.
2.4.4. Ethical approval
The protocol of this study was approved by the Ethics Committee of
Charite-Universit€atsmedizin Berlin in accordance with the 1964 Decla-
ration of Helsinki and its later amendments (reference number EA2/067/
20). All patients and healthy controls gave written informed consent to
participate in the study.
2.5. Statistical software
We performed our statistical analysis in the R software version 4.0.3.
In this analysis, we used the following Bioconductor packages:
hgu133a.db, hgu133plus2.db, IlluminaHumanMethylation450kanno.ilmn12.
hg19, and IlluminaHumanMethylationEPICanno.ilm10b2.hg19 to retrieve
the annotation of the GeneChip HG-U133A, GeneChip U133 þ 2, Infin-
ium HumanMethylation450K Array and HumanMethylationEPIC arrays,
respectively; minfi to estimate the sex of each individual from DNA
methylation data [37]. The R scripts are freely available from the first
and last authors upon request.
3. Results
3.1. Meta-analysis of ACE/ACE2 DNA methylation in ME/CFS patients
The oldest DNA methylation study [27] did not make the data
available and hence, we screened the list of 120 differentially methylated
probes (see table 1 from this study). Although located in 70 genes, these
probes were neither located in ACE nor ACE2. We also screened the list of
differentially methylated probes reported by the study based on the
reduced representation bisulfite sequencing technology (see Additional
File 1 from ref. [33]). Again, none of these probes was in the ACE or ACE2
loci.
For the four array-based studies [28, 29, 30, 32], we conducted a joint
analysis of the respective data in accordance with a meta-analysis. We
first observed that the M-values of the 27 probes under investigation
tended to be uncorrelated with each other (Figure 1B). This observation
supported the use of the Benjamini-Hochberg procedure to adjust the raw
p-values under a multiple testing scenario.
The subsequent analysis suggested four CpG probes in ACE to be
associated with ME/CFS (Figure 1C). The probe cg09920557 belongs to
the TSS region of the gene while the remaining probes (cg19802564,
cg21094739, and cg10468385) are located in the gene body. The best
linear regression models for each probe included both the main effects of
the study indicator and of the disease status and the respective interaction
term (Supplementary Table 3). The statistical interaction between these
two covariates could be seen when plotting the whole data set (Figure 2A).
Although not significant, the estimated main effect of the disease status
was negative for each of the significantly associated probes.
Concerning the probes in ACE2, the only significant association with
ME/CFS was obtained for cg08559914 located in the TSS region of the
gene (Figure 1C). According to the best linear regression model for this
probe, there was a negative association between the respective M-values
and ME/CFS (coefficient estimate ¼ -0.141 with a standard error of
0.048; Figure 2B and Supplementary Table 3). Given that a hypo-
methylated promoter region is typically indicative of an increased
expression of the respective gene, this finding suggested an increased
ACE2 expression in patients with ME/CFS.
We then repeated the same analysis for women and men separately.
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Figure 3. Analysis of ACE/ACE2-related data from eligible microarray-based gene expression studies. (A) Boxplots of the data from these studies (Saiki et al (2008),
ref. [41]; Gow et al (2009); ref. [43]). (B) Forest plot for the study-specific and pooled estimate of the mean of the log2(fold-change) between patients with ME/CFS
and healthy controls using data shown in A.
Table 3. Summary statistics for the gene expression of ACE and ACE2 from the
German female study participants where data of ACE2were only available for 26
affected patients.
Summary statistic Healthy controls ME/CFS patients
N 34 37
Mean age (range), years 37.4 (23; 65) 41.1 (19; 60)
Mean disease duration
since diagnostic (range), months
NA 5.4 (0; 24)
ACE
Geometric mean 0.153 0.144
Interquartile range 0.087 0.073
ACE2
Geometric mean 0.002 0.001
Interquartile range 0.005 0.004
Table 4. Analysis of the linear regression models for the Box-Cox-transformed
ACE and ACE2 mRNA levels where data were only available for 26 ME/CFS
patients.
Analysis Estimate (SE) P-value
Box-Cox transformed ACE
(Intercept) 0.541 (0.032) <0.001
Age 0.001 (0.001) 0.328
Disease Status (ME/CFS) -0.013 (0.018) 0.481
Box-Cox transformed ACE2
(Intercept) 0.307 (0.038) <0.001
Age -0.001 (0.001) 0.137
Disease Status (ME/CFS) -0.006 (0.021) 0.789
J. Malato et al. Heliyon 7 (2021) e07665above (Figure 1D and Supplementary Table 3). For men, we did not find
any significant associations, probably due to data from a single study
[32] (Figure 1E).
3.2. Meta-analysis of ACE/ACE2 gene expression in ME/CFS patients
We first conducted a re-analysis of the two studies in which the
expression levels of ACE or ACE2 were available for each participant
(Figure 3A) [41,43]. In the first study [41], there was evidence for an
increased expression of ACE in patients with ME/CFS (mean of the
log2(fold-change) ¼ 0.265; 95% CI¼(0.089; 0.441)). In the second study
[43], the means of the log2(fold-change) were estimated at 0.012 (95%
CI¼(-0.012; 0.036)) and 0.004 (95% CI¼(-0.014; 0.022)) for the two
probes in ACE. The corresponding estimates for the two probes in ACE2
were -0.038 (95% CI¼(-0.085; 0.009)) and -0.037 (95% CI¼(-0.083;
0.008)) (Figure 3A). The pooled estimates for this study were 0.007 (95%
CI¼(-0.006; 0.020)) and -0.038 (95% CI¼(-0.067; -0.008)) for ACE and
ACE2, respectively.
Although not sharing the data, there was a study [11] that reported a
significant negative association between ME/CFS and ACE2 expression
(see online Supplementary Table 2 of this study). In this case, we ob-
tained the following mean of the log2(fold-change) ¼ -2.396 and 95%
CI¼(-4.518; -0.273).
We then pooled the estimates from different studies for the same
gene: 0.008 (95% CI¼(-0.005; 0.021)) and -0.038 (95% CI¼(-0.068;
-0.009)) for ACE and ACE2, respectively (Figure 3B). Therefore, our
meta-analysis suggested a reduced expression of ACE2 but not of ACE in
patients with ME/CFS when comparing to healthy controls.
Finally, the remaining gene expression studies neither shared the
respective data nor reported any differential ACE/ACE2 expression be-
tween patients and healthy controls.
3.3. Analysis of ACE/ACE2 gene expression from a new female cohort
To complement our findings from the above meta-analysis, we
measured the ACE and ACE2 mRNA levels in PBMCs from 37 women
with ME/CFS (mean age ¼ 41.1 years old) and 34 healthy women (mean
age ¼ 37.4 years old) (Table 3). Patients and healthy participants were
matched for age (Kolmogorov-Smirnov test, p ¼ 0.38). There was no
information about the disease duration for 4 patients. The average dis-
ease duration for the remaining patients was 5.4 months in relation to the
time of diagnosis (range ¼ 0–24 months).
We observed higher mRNA levels of ACE than of ACE2 (Table 4,
Figure 4A). There was no evidence for a significant correlation between
ACE and ACE2 expression levels (Spearman's correlation coefficient ¼
-0.120) (Figure 4B). In contrast to the above meta-analysis, we could not
find a reduced expression of ACE2 in patients with ME/CFS using the7
complete case scenario (Table 4). However, there were 11 (29.7%) of the
37 samples from patients in which the expression level of ACE2 was
below the limit of detection. This proportion of samples was significantly
higher than that for healthy controls given that the expression of ACE2
could be quantified in all the samples (29.7% versus 0%; Pearson's χ2 test,
p ¼ 0.002). Consequently, we could not rule out that the patients with
ME/CFS from this cohort have a decreased expression of ACE2 when
compared to healthy controls. Finally, in accordance with our meta-
analysis, there was no evidence of differential expression of ACE be-
tween patients and healthy controls from this cohort.
4. Discussion
In this work, we investigated potential differences in ACE/ACE2 DNA
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Figure 4. Analysis of ACE and ACE2 expression levels from the German study. (A) Violin plots of ACE (left side) and ACE2 (right side) mRNA raw data (upper row)
and transformed data using a Box-Cox transformation (lower row). (B) Scatterplot between the transformed ACE and ACE2 expression levels (Spearman's correlation
coefficient ¼ -0.120).
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pected to determine the health risk of patients withME/CFS if infected by
SARS-CoV-2. However, we stumbled upon hurdles related to (i) data
unavailability for a possible re-analysis, (ii) availability of data derived
from PBCMs and related subsets in which ACE2 is not particularly
expressed, (iii) studies with unclear data quality, and (iv) studies using
disease case definitions that are not recommended for research. As a
consequence, we could not provide a more definite answer to our main
research question.
Notwithstanding these difficulties, we could identify four CpG probes
on ACE and another one on ACE2with decreased DNAmethylation levels
in patients with ME/CFS. This finding suggested an increased expression
of the respective genes. However, our meta-analysis of public data sug-
gested the opposite. Such decrease in ACE2 expression was partially
confirmed by new data in which there was a significant higher proportion
of samples below the limit of detection in patients with ME/CFS than in
healthy controls. Nonetheless, it was clear that ACE2 is not particularly
expressed in PBMCs from both patients with ME/CFS and healthy con-
trols, as mentioned in the introduction.
In general, ACE2 downregulation is known to occur after host-cell
entry by SARS-CoV-2 [56]. This downregulation is particularly prob-
lematic in individuals affected by cardiovascular diseases, diabetes, and
other medical conditions, due to their low ACE2 levels before the
infection [57]. SARS-CoV-2 infection is then expected to further increase
the ACE:ACE2 ratio, thus, promoting vasoconstriction, increased pro-
duction of ROS and inflammation in patients with these co-morbidities
[23]. In this scenario, a putative reduction of the ACE2 expression
makes patients with ME/CFS similar to these patients with a high risk for
COVID-19. As a consequence, patients with ME/CFS could be considered
a priority group for vaccination by public health authorities. The
fundamental question is then to know whether our findings based on
PBMCs could recreate what occurs in pulmonary epithelial and endo-
thelial cells, the main targets of SARS-CoV-2. Future research should be
conducted to answer this question, as similarly done in past studies
aiming at understanding how the gene expression profiles from PBMCs
could mimick those present in other tissues affecting by a given disease
[58, 59, 60].
Given the residual ACE2 expression in PBMCs under normal condi-
tions, one is tempted to say that SARS-CoV-2 does not infect these cells.
However, earlier studies on SARS-CoV-1 found this virus within T lym-
phocytes, macrophages, and dendritic cells [61]. More recently, an in
vitro study was able to infect PBMCs with SARS-CoV-2 [62]. Monocytes
are particularly susceptible to such infections. In this context, one cannot8
rule out that SARS-CoV-2 might use alternative receptors when infecting
PBMCs.
Among the alternative receptors for SARS-CoV-2, the human trans-
membrane protease serine 2 (TMPRSS2) was suggested as a strong
candidate [63] due to its role on SARS-CoV-1 infection [64, 65]. This
protease seems to induce SARS-CoV-2 cell entry through endocytosis via
a mechanism of ACE2 cleavage [14]. Another candidate receptor is the A
disintegrin and metallopeptidase domain 17 protein (ADAM17) recog-
nized by the immune system as a stress-response signal [66]. Like
TMPRSS2, ADAM17 can also cleave ACE2 but with a reduced viral in-
vasion efficiency [67].
With respect to the role of these proteases in ME/CFS, a targeted gene
expression study analyzed ADAM17 and other stress-response proteins
[41]. This study did not report any differential expression of this protease
between patients with ME/CFS and healthy controls. However, this study
is likely to be affected by a low statistical power due to small sample sizes
for both groups. In addition, one of the selected DNAmethylation studies
suggested a decrease in the DNA methylation levels of one
ADAM17-related CpG probe in patients with ME/CFS [30].
Dipeptidyl peptidase-4 (DPP4), also known as the lymphocyte cell
surface protein CD26, was found to be the main receptor for the Middle
East respiratory syndrome–related coronavirus [68, 69]. In contrast to
ACE2, this surface protein is highly abundant in PBMCs including CD4þ
and CD8þ T cells [18]. Bioinformatic analysis also suggested a strong
interaction potential between this protein and SARS-CoV-2 [70,71].
Finally, DPP4 inhibitors were found to be protective against severe
COVID-19 in patients with diabetes mellitus when compared to RAAS
blockers [72]. After initial concerns, this finding combined with others
suggested an interesting therapeutic avenue against COVID-19 using
DPP4 blockers [73].
Interestingly, there is evidence for an increased proportion of natural
killer cells and T cells expressing DPP4/CD26þ in patients with ME/CFS
[7, 74]. However, the number of DPP4/CD26molecules was significantly
reduced in T lymphocytes and natural killer cells of these patients [74]. If
DPP4 is indeed a relevant receptor for immune-cell invasion by
SARS-CoV-2, research about this receptor should be prioritized when
analyzing PBMCs from patients with ME/CFS.
Sialic acids were also hypothesized as binding receptors used by
SARS-CoV-2, as reported for other human coronaviruses [75]. These
acids are highly expressed in the epithelium cells of the lungs and oral
cavity [76]. In vitro and in silico studies demonstrated the same binding
potential for SARS-CoV-2 [77, 78, 79]. However, the ACE2 glycosylation
inhibition studies suggested that sialic acids on ACE2 receptor prevent
J. Malato et al. Heliyon 7 (2021) e07665ACE2–virus interaction [80, 81]. Again, detailed research on these pu-
tative receptors could help to determine the health risk of patients with
ME/CFS when infected by SARS-CoV-2.
It was suggested that the arousal state experienced by patients with
ME/CFS protects them against microbial infections [82]. This sugges-
tion came from a clinical trial where patients were treated with cloni-
dine to decrease such a state. Treated patients got their symptoms
worsened and had their inflammation markers increased during the
trial. In contrast, basic epidemiological studies reported many patients
with frequent viral infections and flu-like symptoms [3, 4, 83]. The
question is how an infection by SARS-CoV-2 lies in this contrasting
evidence. A possible answer can be given with the assistance of the
so-called sustained arousal model of ME/CFS [84]. According to this
model, a sustained arousal state promotes in the long-run deleterious
alterations of different body systems, including the immune system.
Similar prediction was made by a recent study discussing the natural
history of ME/CFS [85]. If so, patients with longer disease durations are
more likely to show these immunological alterations than patients at
the early stages of the disease. However, we could not analyze the effect
of disease duration on our results, because this variable was not
available in the public data sets included in our meta-analyses.
Finally, our original idea was also to include a meta-analysis of ACE/
ACE2 data from published genome-wide association studies on ME/CFS
[11, 32, 86, 87, 88]. However, we could not materialize this idea,
because such studies did not make their data publicly available. Never-
theless, evidence is scarce for a putative role of ACE/ACE2 poly-
morphisms on ME/CFS. Two studies reported many candidate SNPs for
such association, but none was located in ACE or ACE2 [11,86]. Two
other studies did not find any significant SNPs associated with ME/CFS
[32, 88]. Themost optimistic study reported thousands of SNPs related to
the disease [87]. However, this study did not perform all the basic quality
control checks [89].
5. Conclusions
Notwithstanding the low expression of ACE2 in PBMCs in general,
there is evidence for a decreased expression of the gene in these cells
from patients with ME/CFS. If PBMCs can qualitatively recreate what is
occurring in the main cellular targets of SARS-CoV-2, then patients with
this disease could be at a higher COVID-19 risk. In this regard, a recent
preliminary report suggested that patients with ME/CFS got their
symptoms worsened upon SARS-CoV-2 infection [91]. Altogether, these
patients could be considered a priority group for vaccination against
COVID-19, even though vaccines could trigger ME/CFS [92, 93] or even
exacerbate ME/CFS symptoms as the case of the natural immunization by
SARS-CoV-2. To further consolidate the existing evidence, future
research should prioritize the collection of data from the main cellular
targets in patients with ME/CFS. Further investigation should be also
conducted on alternative SARS-CoV-2 receptors (i.e., DPP4 and sialic
acids). At last, future research should also consider investigating putative
sex differences in patients with ME/CFS given that, in general, men are
more affected by COVID-19 than women [90].
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